Jeffrey Hassall ESA-SRB-ANZBMS 2021

Abstracts this author is presenting:

• Crystal bone is a personalised short-term fracture risk prediction with natural language processing methods — ANZBMS e-Poster Listing - Clinical
• Randomised study to evaluate a secondary prevention program for women with osteoporotic fractures — ANZBMS e-Poster Listing - Clinical
• Romosozumab (Romo) treatment lowers the incidence of new vertebral fractures (Vfx) across all fracture severity grades among women with postmenopausal osteoporosis (PMO) — ANZBMS Clinical Orals
• Estimating relative fracture reduction of romosozumab versus teriparatide for postmenopausal osteoporosis using bone mineral density outcomes — ANZBMS Plenary E-Posters
• Probability of achieving T-scores goals above -2.5 with alendronate (ALN) or romosozumab (ROMO) followed by alendronate or denosumab (DMAB) — ANZBMS e-Poster Listing - Clinical
• Hip fracture has a significant contribution to fragility fracture burden in Ontario Canada — ANZBMS e-Poster Listing - Clinical